Carter, JCheng, LZucker, JMarshall, MPollok, KMurray, MLi, LRenbarger, J2018-08-082018-08-082017-03Carter, J., Cheng, L., Zucker, J., Marshall, M., Pollok, K., Murray, M., … Renbarger, J. (2017). Use of Precision Medicine Molecular Profiling of Baseline Tumor Specimen May Not Benefit Outcomes in Children With Relapsed or Refractory Pediatric Sarcomas. Clinical Pharmacology and Therapeutics, 101(3), 328–330. https://doi.org/10.1002/cpt.5990009-9236https://hdl.handle.net/1805/17028Given the poor prognosis of pediatric patients with relapsed or refractory sarcomas, discovery and implementation of innovative approaches and tools to guide therapy are urgent needs. This retrospective pilot study evaluated the impact of relapse and refractory therapies aligned with molecular characterization of biopsies collected at the time of primary diagnosis.en-USPublisher Policyrefractory therapytumorMolecular profileArticle